Eric J Burks, MD
Clinical Associate Professor, Pathology
Biography
Eric Burks, MD is a Clinical Associate Professor of Pathology at the Chobanian and Avedisian School of Medicine. After graduating medical school, he had two fellowship: one in Surgical Pathology at Harvard Medical School and another in Hematopathology at Johns Hopkins Medical Institution. Only recently, as of April 2018, did he join Boston University. With him he brings extensive experience as a lecturer, mentor, and physician. His research is particularly notable given that he has received both the American Cancer Society Institutional Research Grant Medical Student Award and the American Society of Hematology Medical Student Award.
Other Positions
- Member, BU-BMC Cancer Center, Boston University
Education
- University of New Mexico School of Medicine, MD
- New Mexico State University, BS
Publications
- Published on 6/10/2024
Steiner D, Sultan L, Sullivan T, Liu H, Zhang S, LeClerc A, Alekseyev YO, Liu G, Mazzilli SA, Zhang J, Rieger-Christ K, Burks EJ, Beane J, Lenburg ME. Identification of a gene expression signature of vascular invasion and recurrence in stage I lung adenocarcinoma via bulk and spatial transcriptomics. bioRxiv. 2024 Jun 10. PMID: 38915565.
Read at: PubMed - Published on 5/22/2024
Steiner D, Park JA, Singh S, Potter A, Scalera J, Beane J, Suzuki K, Lenburg ME, Burks EJ. A computed tomography-based score indicative of lung cancer aggression (SILA) predicts lung adenocarcinomas with low malignant potential or vascular invasion. Cancer Biomark. 2024 May 22. PMID: 39058440.
Read at: PubMed - Published on 5/22/2024
Burks EJ, Sullivan TB, Rieger-Christ KM. Pulmonary adenocarcinoma of low malignant potential defines indolent NSCLC associated with overdiagnosis in the national lung screening trial. Cancer Biomark. 2024 May 22. PMID: 39058439.
Read at: PubMed - Published on 4/8/2024
Zheng Y, Conrad RD, Green EJ, Burks EJ, Betke M, Beane JE, Kolachalama VB. Graph attention-based fusion of pathology images and gene expression for prediction of cancer survival. IEEE Trans Med Imaging. 2024 Apr 08; PP. PMID: 38587959.
Read at: PubMed - Published on 4/6/2024
Gindra RH, Zheng Y, Green EJ, Reid ME, Mazzilli SA, Merrick DT, Burks EJ, Kolachalama VB, Beane JE. Graph Perceiver Network for Lung Tumor and Bronchial Premalignant Lesion Stratification from Histopathology. Am J Pathol. 2024 Jul; 194(7):1285-1293. PMID: 38588853.
Read at: PubMed - Published on 11/13/2023
Ma L, Sullivan TB, Rieger-Christ KM, Yambayev I, Zhao Q, Higgins SE, Yilmaz OH, Sultan L, Servais EL, Suzuki K, Burks EJ. Vascular invasion predicts the subgroup of lung adenocarcinomas =2.0 cm at risk of poor outcome treated by wedge resection compared to lobectomy. JTCVS Open. 2023 Dec; 16:938-947. PMID: 38204657.
Read at: PubMed - Published on 7/8/2023
Jamil ML, Perecman A, Sherman A, Sullivan T, Christ K, Hansma A, Burks E, Vanni AJ. Urinary microbiome differences between lichen sclerosus induced and non-lichen sclerosus induced urethral stricture disease. World J Urol. 2023 Sep; 41(9):2495-2501. PMID: 37421420.
Read at: PubMed - Published on 12/25/2022
Suaiti L, Sullivan TB, Rieger-Christ KM, Servais EL, Suzuki K, Burks EJ. Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma. Clin Lung Cancer. 2023 May; 24(3):e126-e133. PMID: 36631388.
Read at: PubMed - Published on 10/27/2022
Zheng Y, Gindra RH, Green EJ, Burks EJ, Betke M, Beane JE, Kolachalama VB. A Graph-Transformer for Whole Slide Image Classification. IEEE Trans Med Imaging. 2022 Nov; 41(11):3003-3015. PMID: 35594209.
Read at: PubMed - Published on 10/26/2022
Prokaeva T, Klimtchuk ES, Feschenko P, Spencer B, Cui H, Burks EJ, Aslebagh R, Muneeruddin K, Shaffer SA, Varghese E, Berk JL, Connors LH. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis. Amyloid. 2023 Jun; 30(2):141-152. PMID: 36286264.
Read at: PubMed
View 43 more publications: View full profile at BUMC